Compare Suncor Energy Inc. (SU) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Suncor Energy Inc. trades at $75.96 (market cap $87.48B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Suncor Energy Inc. is far larger — about 11.6× Spyre Therapeutics Inc. Common Stock's market cap, and Suncor Energy Inc. pays a 2.26% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SU | SYRE | |
|---|---|---|
Market Cap | $87.48B | $7.52B |
Volume | 3,692,639 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $75.89 | $108.92 |
52-Week Low | $38.17 | $22.18 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $94.00B | $6.52B |
Dividend Yield | 2.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $75.89, up 3.24% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 14.32, net income margin of 14.7%, and consistent cash flow generation. Recent news highlights strategic asset divestitures and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings.
Outlook remains favorable given SU's integrated oil sands operations and aggressive shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges, but the company's strong balance sheet and improving debt metrics provide stability. Current valuation appears reasonable relative to earnings potential.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
